Trial Profile
Prospective study of efficiency of fibrosis score in computed tomography as predictor after treatment with Nintedanib for idiopathic pulmonary fibrosis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 17 May 2016 New trial record